Posted inBiotechnology
FDA misses IND deadline for Coya’s ALS asset, cites lack of resources
The FDA has missed the date for Coya Therapeutics’ investigational new drug (IND) application, citing a lack of resources and…
Posted inMedical Technology
Siemens Healthineers, Philips project softer tariff hit following US-EU deal
Siemens Healthineers raised its fiscal year 2025 outlook after reporting stronger-than-expected third-quarter results, boosted by growth in its Varian and…
Posted inBiotechnology
Vyne’s lead BET inhibitor fails phase 2 vitiligo trial, sinking stock
The bad news keeps on creeping toward Vyne Therapeutics’ BET inhibitor platform. Weeks after the biotech gave up on a…
Posted inBiotechnology
Investors whale on Cardiff, sinking stock after seeing updated colorectal cancer data
Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data it believes can support talks…
Posted inBiotechnology
Madrigal pens $2B pact for CSPC’s preclinical GLP-1 with eye on Rezdiffra MASH pairing
Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up…
Posted inBiotechnology
GSK’s anti-TIM-3 antibody flunks phase 3 trial as anti-TIGIT failure costs $629M
GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more…
Posted inBiotechnology
Kissei pays Viridian $70M to challenge Amgen for Japanese eye disease market
Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye disease (TED) drug…
Posted inBiotechnology
Merbecovirus S2 Vaccines Trigger Cross-Reactive MERS Protection
In a groundbreaking study recently published in npj Viruses, a team of researchers led by Halfmann and colleagues has unveiled…
Posted inGenetics
Fyodor Urnov Discusses CRISPR Cures
In a keynote talk during GEN’s “The State of CRISPR & Genome Editing” virtual summit, originally broadcast on June 11,…
Posted inGenetics
Base Editing and More
In this talk in GEN’s “The State of CRISPR & Genome Editing” virtual summit, originally broadcast on June 11, 2025,…